comparative effectiveness

Research in Review

Novel Prognostic Biomarker Identified in DLBCL

06/23/2017

JCP Editors

A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...

A new...

06/23/2017

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitor Improves Response Rates, Survival Times in Certain Patients With NSCLC

06/23/2017

JCP Editors

A programmed death 1 (PD-1) inhibitor is associated with similar efficacy to chemotherapy in patients with non-small cell lung cancer (NSCLC), but improves response rates and survival times in subgroups of patients,...

A...

06/23/2017

Journal of Clinical Pathways

Research in Review

DLBCL Survival Outcomes Improved With Combination Therapy

06/22/2017

JCP Editors

Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...

...

06/22/2017

Journal of Clinical Pathways

Research in Review

Hypomethylating Agents Improve Survival in Older Patients With CMML

06/19/2017

JCP Editors

Older patients with chronic myelomonocytic leukemia (CMML) who are treated with hypomethylating agents reduce their risk of disease-related mortality by 28%, according to new research published in Cancer (published...

Older...

06/19/2017

Journal of Clinical Pathways

Research in Review

RA Relapse Prediction Tool Decreases Cost of Treatment

06/19/2017

JCP Editors

Researchers developed a method of identifying candidates with rheumatoid arthritis (RA) for dose reduction of disease modifying anti-rheumatic drugs (DMARDs). ----- Related Content Certolizumab combo helps curb RA...

...

06/19/2017

Journal of Clinical Pathways

Research in Review

PD-L2 Expression May Indicate Response to Immunotherapy in Head and Neck Cancer

06/15/2017

JCP Editors

A recent study suggests that immunotherapies targeting both PD-L1 and PD-L2 may enhance response rates for patients with head and neck squamous cell carcinoma (HNSCC), published in Clinical Cancer Research (published...

A...

06/15/2017

Journal of Clinical Pathways

Research in Review

CAR T-Cells Improve Outcomes in Multiple Myeloma

06/13/2017

JCP Editors

Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...

...

06/13/2017

Journal of Clinical Pathways

Research in Review

High Response Rates With New Treatment for Aggressive B-Cell Lymphoma

06/13/2017

JCP Editors

In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product. ----- Related Content B-Cell ALL Disease Burden May...

In a...

06/13/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Improves Standard of Care for Multiple Myeloma

06/08/2017

JCP Editors

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...

Adding...

06/08/2017

Journal of Clinical Pathways

Research in Review

Prolonged PFS, QoL in Ovarian Cancer After Maintenance Therapy

06/08/2017

JCP Editors

Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival (PFS) by almost 7 months, according to results of a...

Women...

06/08/2017

Journal of Clinical Pathways